Mesoblast Ltd - ESG Rating & Company Profile powered by AI
Complete ESG assessment of Mesoblast Ltd can be accessed by logging in. This page is a free ESG analysis covering Mesoblast Ltd. The report of Mesoblast Ltd uses information from across the internet and also from available documents by Mesoblast Ltd.
Mesoblast Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 4.8, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 315 | Pluristem Therapeutics Inc | 7.2 | High |
| 315 | Regeneron Pharmaceuticals Inc | 7.2 | High |
| 326 | Mesoblast Ltd | 7.1 | High |
| 326 | BOD Australia Ltd | 7.1 | High |
| 326 | Abionyx Pharma SA | 7.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Mesoblast Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Mesoblast Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Mesoblast Ltd report the average age of the workforce?
Sign up for free to unlockDoes Mesoblast Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Mesoblast Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Mesoblast Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Mesoblast Ltd offer flexible work?
Sign up for free to unlockDoes Mesoblast Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Mesoblast Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Mesoblast Ltd conduct supply chain audits?
Sign up for free to unlockDoes Mesoblast Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Mesoblast Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Mesoblast Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Mesoblast Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Mesoblast Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Mesoblast Ltd disclose water use targets?
Sign up for free to unlockDoes Mesoblast Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Mesoblast Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Mesoblast Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Mesoblast Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Mesoblast Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Mesoblast Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Mesoblast Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Mesoblast Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Mesoblast Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Mesoblast Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Mesoblast Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Mesoblast Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Mesoblast Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Mesoblast Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Mesoblast Ltd disclose its waste policy?
Sign up for free to unlockDoes Mesoblast Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Mesoblast Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Mesoblast Ltd disclose energy use targets?
Sign up for free to unlockDoes Mesoblast Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Mesoblast Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Mesoblast Ltd
These potential risks are based on the size, segment and geographies of the company.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.